EMA’s transformative treatments of 2020
1
In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
Despite the challenges presented by COVID-19, 2020 was a bumper year for approvals by the European Medicines Agency (EMA). According to their latest report, the EMA recommended a total of 97 human medications for approval in 2020, including 22 orphan drugs and 39 new active substances.
In this article,
European Pharmaceutical Review’s Hannah Balfour summarises the trial findings for the treatments reported to significantly advance their therapeutic areas during 2020.
The EMA’s Human Medicines Highlights 2020 report lists all the medicines recommended for approval in 2020 by their indications. Overall, oncology had the most approvals – 21 in total – followed by haematology/haemostaseology with 14 and infectious diseases and pneumology/allergology, each with 11. Oncology also had the largest number of
The current and future landscape of HIV treatments and vaccines
4
Dr Caroline Forkin from ICON discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
“Globally, great strides have been made in HIV testing and treatment,” states a new whitepaper on the evolution and projected progress of HIV treatments. Including post-exposure prophylaxis (PEP), there are a range of antiretroviral therapies available at present to treat HIV. Other recent developments to prevent the spread of HIV include pre-exposure prophylaxis (PrEP), which is the pre-emptive use of antiretroviral therapy by individuals substantially at risk of contracting the virus. However, researchers are still seeking to develop improved therapies and vaccines to combat the virus.
Careers - European Pharmaceutical Review europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
COVID-19 vaccines: how important is the vial?
8
In this article we discuss how the problems associated with glass vial packaging may disrupt COVID-19 vaccine distribution and explore some of the latest innovations to overcome it.
The glass vials into which vaccines and most other biologic drugs are packaged have changed very little in the past 100 years. Traditional borosilicate glass vials have several safety concerns associated with them, from the possibility of breakages to their potential to delaminate. To find out how these issues affect pharma and their possible impact on COVID-19 vaccine distribution,
European Pharmaceutical Review’s Hannah Balfour spoke with Lawrence Ganti, Chief Business Officer of SiO2, an innovative materials science company who has developed hybrid vials for biologics.